Differences in major and minor histocompatibility antigens between donor and recipient trigger powerful graft-versus-host reactions after allogeneic hematopoietic stem cell transplantation (HSCT). The clinical effects of alloreactivity present a Janus-face: detrimental graft-versus-host disease increases non-relapse mortality, beneficial graft-versus-malignancy may cure the recipient. The ultimate consequences on long-term outcome remain a matter of debate. We hypothesized that increasing donor-recipient antigen matching would decrease the negative effects, while preserving antitumor alloreactivity. We analyzed retrospectively a predefined cohort of 32 838 such patients and compared it to 59 692 patients with autologous HSCT as reference group. We found a significant and systematic decrease in non-relapse mortality with decreasing phenotypic and genotypic antigen disparity, paralleled by a stepwise increase in overall and relapse-free survival (Spearman correlation coefficients of cumulative excess event rates at 5 years 0.964; P o 0.00; respectively 0.976; P o0.00). We observed this systematic stepwise effect in all main disease and disease-stage categories. The results suggest that detrimental effects of alloreactivity are additive with each step of mismatching; the beneficial effects remain preserved. Hence, if there is a choice, the best match should be donor of choice. The data support an intensified search for predictive genomic and environmental factors of 'no-graft-versus-host disease'.
INTRODUCTION
For many patients with congenital or acquired severe hematological disorders, allogeneic hematopoietic stem cell transplantation (HSCT) offers unique potential for cure. Bone marrow and peripheral blood from family members or unrelated volunteer donors serve as a source of stem cells for syngeneic or allogeneic transplants. Worldwide annual numbers of allogeneic and autologous HSCT currently exceed sixty thousand and figures are still rising. [1] [2] [3] [4] Several elements contribute to the success of HSCT. The conditioning therapy preceding the transplant prepares the recipient (host) to accept the graft, and reduces tumor load. The infusion of healthy allogeneic hematopoietic stem cells restores hematopoiesis and installs an alloreactive immune surveillance of the tumor. Indeed, allogeneic HSCT provided the first proof of principle that immune mechanisms can eradicate malignant disease. However, a double immunological barrier adds complexity, including host-versus-graft (graft rejection) and graftversus-host reactions. 5, 6 Both barriers increase with the degree of disparities in major and minor histocompatibility antigens. Graft rejection is always associated with detrimental effects for the patient. [5] [6] [7] [8] [9] In contrast, the graft-versus-host reactions present a Janus face. The detrimental part, graft-versus-host disease, remains the most important direct or indirect cause for nonrelapse mortality after allogeneic HSCT. 1, [5] [6] [7] The 'other face', the graft-versus-malignancy effect, is desired and may result in cure of the recipient. 10 HSCT presents also as role model of precision medicine: one individual donor is selected for one individual recipient based on genetic findings. Best donor choice and best matching for minor and major histocompatibility antigens to modulate the two divergent alloreactive effects have been a matter of debate since the very beginning. 11 This discussion has intensified in recent years. The lack of a Human Leukocyte Antigen (HLA)-identical sibling donor for many patients has triggered the search for alternative donors, including mismatched family members or partially matched unrelated donors. [12] [13] [14] [15] The degree of matching needed for an 'acceptable' unrelated donor is still not settled. Some approaches postulate' a donor option' for every patient. 16 Indeed, the ready availability and the promising early results have led to a substantial increase in the use of haploidentical mismatched family-donor transplants. 12, 17 Results from large series and with a long follow-up, however, are lacking. In this context, and in view of the need for better data in the present precision medicine initiative, 18 we analyzed a predefined large cohort of patients with a confirmed follow-up of 8 years. 19 We hypothesized a donor type hierarchy based on phenotypic and genotypic differences between donor and recipient in major (defined by HLA) and minor (defined by HY) histocompatibility antigens and analyzed non-relapse mortality, relapse-free and overall survival in specified donor type groups.
MATERIALS AND METHODS

Study design and patient population
This retrospective observational analysis is based on a previously published cohort of 102 549 patients treated between 1999 and 2006 with HSCT for an acquired hematological malignancy from 1999 to 2006 (Table 1) and reported by 404 teams to the European Society for Blood and Marrow Transplantation (EBMT) database (www.ebmt.org). 19 This corresponds to 93% of all patients transplanted during this period by the participating teams with these indications. The patient' survival data were updated as of 1 January 2015. The final analysis was restricted to patients with full information on all variables integrated into the analysis. It includes 32 838 patients with a first allogeneic HSCT (35%) and 59 692 patients with autologous HSCT (65%) as reference group (Total N = 92 530 patients). The main endpoint in all analyses was 'death' due to non-relapse mortality, leading to estimates for non-relapse mortality, overall survival and relapsefree survival in a competing risk framework. All the data were censored at 8 years post HSCT to provide for a homogeneous observation period.
All EBMT teams are required to obtain patients' consent and to have internal review board approval for their transplant programs and for data transfer to EBMT. The analysis did not use individual patient data; no ethics approval was mandated.
Definitions
Definitions relied on the pre-specified hypothesis that increasing phenotypic and genotypic matching for minor and major histocompatibility antigens would be associated with decreasing effects of graft-versushost but preserve antitumor activity. Donor type was used as predefined in the EBMT database and as reported by the transplant teams, split into syngeneic donor, HLA-identical sibling donor, matched other family donor, matched unrelated donor, mismatched unrelated donor and mismatched family donor (Table 2) . Specific HLA-antigens were not collected in this database, but 'donor type' served as a surrogate marker for the numbers of potential phenotypic and genotypic mismatches for major and minor histocompatibility antigens. For the latter, we used the donor-recipient gender combination and defined the female donor-male recipient combination as HY + and all other donor-recipient gender combinations as HY − . By definition, HY status is HY − for autologous and syngeneic transplants. HY status had no significant additional effect in mismatched related on unrelated transplants (data not shown); hence, these two donor types were not split by HY. Autologous HSCT served as reference group, since no alloreactivity occurs after such transplants.
Statistical analysis
The above-mentioned a priori ordering was provided to the statistician before the data were analyzed and was not modified in any respect during the analyses. The focus of the statistical approach was not to prove the significance of any specific risk (sub) factor in its association with the hazard of the outcomes but on the establishment of a pre-specified 'dose response relationship' in the framework of a model which would not impose such 'proportionality'. Hence, the use of a COX model with the a priori ordered risk categories is impossible. To maximize power of the analyses, a stratified COX model was used where each of the ordered risk categories has its own base line curve. Since then by definition the Hazard Ratio comparing the 10 a priori specified categories would not be retained by the model to be constant, comparison of those categories is impossible using a single Hazard Ratio. We integrated previously described standard risk factors 20, 21 and used the cumulative hazard estimates in the stratified models. 22 The model characterizes the differences between the 10 categories and allows their ordering to arbitrarily change over follow-up time. Survival curves over an 8-year period were modeled using donor type as a predefined stratification variable.
All models contained previously established key risk factors as continuous or factorized covariates 20, 21 (Supplementary Figure 1) : main disease (acute leukemia, chronic leukemia, myelodysplastic syndrome/ myeloproliferative neoplasias, lymphoma and plasma cell disorders; Supplementary Figure 1a Figure 1e ) and, T-cell depletion (TCD-vs TCD+). As microeconomic variables (covariates at the center level), we used center patient volume and center program duration. We used both as continuous variables in the model but recoded them into 5 categories to avoid problems with outliers. 19 Calendar year was used as a continuous covariate. Relapse, as provided by the database and non-relapse mortality were acknowledged as competing risks.
We used the cumulative hazard or-more generically speaking-the cumulative event rate as the primary measure to compare the various ordered risk categories. The difference in the cumulative event rates was denoted by the word 'cumulative excess event rate' (CEER), in strict analogy to the notion of 'force of mortality' 22 in the case of the outcome being death. Therefore, our CEER can be interpreted as 'excess mortality rate'. The CEER does not measure a cumulative incidence of the outcome itself.
For statistical testing of the null hypothesis of 'no ordering over the 10 donor types' versus the alternative hypothesis 'systematic increase/ decrease of a cumulative event rate', we used a non-parametric Spearman correlation coefficient between the CEER and the order number of the risk category, excluding the reference category. All analyses were performed by SPSS version 22/24.
RESULTS AND DISCUSSION
Patient population
The analysis comprised 32 838 recipients of allogeneic HSCT and 59 692 patients with autologous HSCT as reference group (Table 1) . In this heterogeneous population, allogeneic HSCT was preferentially used for acute leukemias (N = 19 554; 76% allogeneic), chronic leukemias (N = 6698; 83% allogeneic) and myelodysplastic/myeloproliferative disorders (N = 3122; 94% allogeneic); autologous HSCT was preferentially used for lymphoma (N = 29 476; 91% autologous) and plasma cell disorders (N = 22 582; 97% autologous).
The 10 groups of donor types, defined by their degree of phenotypic and genotypic matching for minor and major histocompatibility antigens (see Table 2 Table 2 ). The donor groups differed significantly with respect to disease, disease stage, conditioning and T-cell depletion status (Table 1) . There were significant differences between the 404 participating HSCT centres from 25 European countries regarding their center experience, patient volume and accreditation status. There were significant changes in the indications for HSCT over time. 19 'Standard' risk factors and outcome The analysis confirmed previously defined risk factors. 20, 21 Outcome differed between the five main disease categories. Survival estimates for patients with autologous and allogeneic HSCT showed non-proportional hazards for the main disease categories (Supplementary Figure 1a) . Overall survival decreased from good risk to intermediate and poor risk disease-stage due to increasing relapse incidence and increasing non-relapse mortality in all disease categories and for all donor types (Supplementary Figure 1b) .
Overall survival decreased with increasing recipient and donor age due to increasing non-relapse mortality after both, allogeneic and autologous HSCT (Supplementary Figures 1c and d) . Transplant techniques such as reduced intensity conditioning were associated with overall survival in patients with allogeneic HSCT (Supplementary Figure 1e) . 
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Degree of donor-recipient matching and outcome: donor type hierarchy The data confirmed the hypothesis; they showed a clear donor type hierarchy. Non-relapse mortality increased significantly and systematically with each step of mismatching between donor and recipient, as shown by the cumulative event excess rate compared to the reference group autologous HSCT (CEER; Spearman coefficient 0.964; P o 0.001; Figure 1a ; Table 3 ). 22 In parallel, relapse-free and overall survival decreased by each step. Consequently, the cumulative excess event rate for death was lowest after syngeneic HSCT (CEER = − 0.10) and increased systematically and significantly from HLA-identical, HY − siblings (CEER 0.04) to mismatched related (CEER 0.57) donor HSCT (Spearman coefficient for overall survival 0.976; P o 0.001; Table 3; Figure 1b ). Probability of overall survival improved significantly and systematically with each step of matching from 31% at 5 years for the patients with a mismatched related donor HSCT to 54% with an HLA-identical, HY − sibling donor transplant, and to 69% with a syngeneic HSCT (Figure 2 ; Table 3 ). Relapse-free survival increased as stepwise from 26% at 5 years with a mismatched related donor HSCT to 43% with an HLA-identical HY − sibling donor transplant, and 55% for the 201 patients with a syngeneic HSCT (Table 3) .
In summary, the data showed a systematic, monotonous decrease in the cumulative excess death rate and an increase in overall and relapse-free survival with each step of matching for HLA, and in each HY − versus HY + constellation (Table 1 ; Figure 1 ). The donor type groups with no mismatch had the best overall long-term survival (Figure 2 ). Detailed subgroup analyses showed the same systematic effects of matching on overall survival and relapse-free survival for all main disease categories and the three disease stages (Supplementary Figure 2; Supplementary Tables 1a and b). The analyses confirmed the same systematic and stepwise effects of donor type on the cumulative excess event rates in overall survival, non-relapse mortality and relapse-free survival for all main disease categories and all three disease stages ( Supplementary Tables 2a and b) . Results showed the same effects when one disease category with large numbers of both, allogeneic and autologous HSCT was analyzed, acute myeloid leukemia (Spearman rank for overall survival 0.903; P o0.000). The Spearman rank correlation of the cumulative excess event rates for non-relapse mortality, overall and relapse-free survival confirmed the consistent and systematic association with donor type in each disease category (Supplementary Table 3a ) and each disease stage (Supplementary Table 3b ). Acceptance criteria for 'matched unrelated donors' were not strictly defined, differed by centers and included 8/8 or higher, 10/10 or higher or 12/12 antigen matches by high resolution and low resolution typing.
d Acceptance criteria for 'mismatched unrelated donors' were not strictly defined, differed by centers and included less than 10/10 or less than 8/8 antigen matches by high resolution and low resolution typing, but rarely less than 7/8 matches. e Includes to a broad extent full haplotype ( = 6/12 antigen) mismatched family donors.
Hence, the data showed a significant, systematic and stepwise decrease in non-relapse mortality with increasing phenotypic and genotypic matching between donor and recipient for minor and major histocompatibility antigens, accompanied by a parallel systematic improvement in relapse-free and overall survival. The findings confirmed our hypothesis. They suggest a basic principle of the Janus face alloreactivity in HSCT. The detrimental effects of graft-versus-host disease, which ultimately result in non-relapse mortality, increase in a cumulative pattern with each step of mismatching; the beneficial effects of relapse reduction remain maintained with matching. This fits with previous findings; negative patient, donor and disease-related pre-transplant risk factors act additively. 20, 21 There are some caveats and limitations. We had no detailed information on the exact numbers of disparities for HLA and minor antigens. We selected 'donor type' as reported and as defined by the EBMT data collection system. We used it as a marker for phenotypic and genotypic differences in HLA antigens between donor and recipient (www.ebmt.org). We used the female donormale recipient gender combination as marker for one group of minor histocompatbility antigens, the HY complex and ignored other minor antigens. 23, 24 On the basis of these well-established markers, we postulated a donor type hierarchy and found it confirmed. We had no details on prevention and treatment or on onset and degree of acute and chronic graft-versus-host disease, and did not compare patients with or without graft-versus-host disease. However, 'allogeneic effects' are required for graft-versushost disease, and graft-versus-host disease is the main contributor to non-relapse mortality; allogeneic effects are absent in autologous HSCT.
1,25 Therefore, we considered the excess of non-relapse mortality, as compared to autologous HSCT as reference group, as an acceptable endpoint and surrogate marker for detrimental alloreactivity. We did not perform a formal analysis of relapse incidence as a marker for graft-versus-malignancy effects. Other effects besides alloreactivity determine relapse, such as genetic disease-related factors, and presence or absence of minimal residual disease. This lack of data, the different types of relapse in the individual disease categories, and the overriding effect of early non-relapse mortality in recipients with increasing HLA-disparity hamper a direct relapse analysis. We did concentrate on non-relapse mortality, and considered the parallel effects on relapse-free and overall survival as estimates for the beneficial effects of alloreactivity. The patient population was heterogeneous and some subgroups were small. Nevertheless, the analysis did profit from the large predefined cohort. It integrated the key well-described transplant risk factors and adjusted for micro-and macroeconomic risk factors in the analysis. 11, 19, 20 The large number of patients, the long follow-up time with a minimum of 8 years, and the systematic pattern in all disease categories and disease stages render it likely that the observations of a donor type hierarchy are true findings.
The results carry major implications. They clarify the role of matching in times when HSCT should provide for each patient a better outcome regarding overall survival, quality of life and costs; 19 they add caution to current concepts to 'find a donor option for every patient. [12] [13] [14] [15] [16] [17] They fit with recent studies that well-matched unrelated donor HSCT showed results similar to those with matched sibling donors. They suggest complete HLA-typing (12 out of 12 antigens) of unrelated donors 26, 27 before decision-making. One argument might be that results from our study on transplants performed more than 10 years ago are no longer relevant in today's times. Outcome has improved, novel techniques have appeared. 17 The use of cyclophosphamide shortly after the infusion of stem cell as graft-versus-host disease prophylaxis appears to reduce incidence and severity of graft-versus-host disease. Some early promising results have triggered a rapid expansion in the use of haploidentical donors; still, they await confirmation. [12] [13] [14] [15] [16] Recent results from a large EBMT study with high-risk AML patients indicate a similar outcome at 2 years after haploidentical as compared to 10/10 antigen matched unrelated donor transplants. Non-relapse mortality was reported to be higher, relapse incidence to be lower after haploidentical HSCT, 28 follow-up was short and risk profiles of the patients different. These early data remain compatible with our findings. The donor type hierarchy prevailed in our long-term analysis regardless of transplant technique. Long-term follow-up is missing with novel techniques. Hence, as of today, if there is a choice, the best match should be donor of choice.
Furthermore, results might redirect research in the present precision medicine initiative on genetic and environmental factors: '..to bring the right prevention and the right treatment for the right patient at the right time' (http://euapm.eu/). Focus has been on factors associated with 'disease' in order to find targets for interventions, 29 in the context of HSCT with graftversus-host disease. A shift in policies might be indicated towards factors associated with 'no-disease', hence 'no graft-versus-host disease'. About one-third of all HLA-identical sibling donor recipients never ever develop any graft-versus-host disease. 30 The reasons for absence of graft-versus-host disease are largely unknown. They might be strictly related to differences between donor and recipient in major or minor histocompatibility antigens. There are indications for such constellations. [31] [32] [33] Environmental factors might as well influence presence or absence of graftversus-host disease; the microbiome of the gut has long been in focus and regained most recent interest. 33, 34 If successful, a 'no graft-versus-host disease' constellation might favor an early low cost transplant with no need for immunosuppression post grafting, and save costs and suffering. A high-risk graft-versushost disease constellation might indicate a 'no transplant' treatment strategy.
In summary, our data showed a donor type hierarchy in HSCT where non-relapse mortality decreased stepwise with increasing antigen matching, accompanied by a stepwise increase of overall survival. The beneficial effects of alloreactivity remained, while the detrimental effects decreased. This news might open up new avenues in the era of precision medicine, and launch the search for predictive genomic and environmental factors for 'no graftversus-host disease'.
